Shots:

• Celltrion launches the world's first SC formulation of infliximab (120mg- q2w- fd- as a pre-filled pen (auto-injector) in Canada for the treatment of adult patients with RA
• Remsima SC will be the first product to be commercially available in Canada under the new direct sales marketing strategy and is supported by the CELLTRION CONNECT patient support program
• The biosimilar is approved in Canada for use in combination with MTX to reduce the signs and symptoms- inhibit the progression of structural damage and improvement in physical function in adult patients with RA

  | Ref: Celltrion | Image: Celltrion